JiaRuanMDPhD

Hematologic Oncology

Professor of Clinical Medicine, Weill Cornell Medical College

Overview of Dr. Ruan

Dr. Jia Ruan is an oncologist in New York, NY and is affiliated with multiple hospitals in the area, including New York-Presbyterian Hospital, New York-Presbyterian Hospital, New York-Presbyterian Hospital, and NewYork-Presbyterian/Columbia University Irving Medical Center. She received her medical degree from Weill Cornell Medicine and has been in practice 18 years. Dr. Ruan accepts several types of health insurance, listed below. She is one of 375 doctors at New York-Presbyterian Hospital and one of 119 doctors at NewYork-Presbyterian/Columbia University Irving Medical Center who specialize in Oncology. She also speaks multiple languages, including Chinese (Mandarin). She has more than 100 publications and over 500 citings.

Office
520 E 70th St
# Starr
New York, NY 10021
Book by Phone+1(747) 900-4479

Fax+1 212-746-7481

Education & Training

New York Presbyterian Hospital (Cornell Campus)Fellowship, Hematology and Medical Oncology, 2003 - 2005
Stanford Health Care-Sponsored Stanford UniversityFellowship, Hematology, 2002 - 2003
Stanford Health Care-Sponsored Stanford UniversityResidency, Internal Medicine, 1999 - 2001
Weill Cornell MedicineClass of 1999

Certifications & Licensure

CA State Medical License 2000 - Present
NY State Medical License 2003 - 2026
American Board of Internal Medicine Hematology

Awards, Honors, & Recognition

CMS Meaningful Use Stage 1 Certification EpicCare Ambulatory EMR, Epic Systems Corporation, 2011-2013
Summa cum laude, BA in Biochemistry and Molecular Biology Washington University in St. Louis
AOA member Alpha Omega Alpha Honor Medical Society
Fellow’s Teaching Award Division of Hematology, Stanford University Medical Center
ASH Clinical Research Training Institute (CRTI) American Society of Hematology
ASCO Young Investigator Award Americal Society of Clinical Oncology
ASCO Career Development Award Americal Society of Clinical Oncology
NIH / NHLBI K08 Award National Institute of Health
Join now to see all

Clinical Trials

Phase I Trial of Anti-CD74 (hLL1) Antibody Therapy in B Cell Malignancies Start of enrollment: 2007 Jun 01
Completed
Phase 1
Lenalidomide Plus Rituxan for Untreated Mantle Cell Lymphoma Start of enrollment: 2011 Jul 29
Completed
Phase 2
A Dose Escalation Study of OMP-52M51 in Subjects With Lymphoid Malignancies Start of enrollment: 2012 Oct 01
Completed
Phase 1
Romidepsin in Combination With Lenalidomide in Adults With Relapsed or Refractory Lymphomas and Myeloma Start of enrollment: 2012 Dec 01
Completed
Phase 1, Phase 2
ECHELON-2: A Comparison of Brentuximab Vedotin and CHP With Standard-of-care CHOP in the Treatment of Patients With CD30-positive Mature T-cell Lymphomas Start of enrollment: 2013 Jan 31
Completed
Phase 3
A Phase 2 Multicenter Study of High Dose Chemotherapy With Autologous Stem Cell Transplant Followed by Maintenance Therapy With Romidepsin for the Treatment of T Cell Non-Hodgkin Lymphoma Start of enrollment: 2013 Jul 16
Active, not recruiting
Phase 2
Cellular Immunotherapy Treatment Antigen-Directed for EBV Lymphoma Start of enrollment: 2014 Sep 01
Terminated
Phase 2
Ibrutinib in Combination With Lenalidomide and Rituximab in Participants With Relapsed or Refractory Diffuse Large B-Cell Lymphoma Start of enrollment: 2014 Mar 13
Completed
Phase 1, Phase 2
CC486-CHOP in Patients With Previously Untreated Peripheral T-cell Lymphoma Start of enrollment: 2018 Jun 01
Completed
Phase 2
Acalabrutinib-Lenalidomide-Rituximab in Patients With Untreated MCL Start of enrollment: 2019 Oct 11
Active, not recruiting
Phase 2
Join now to see all

Publications & Presentations

PubMed

1 citations
Valemetostat monotherapy in patients with relapsed or refractory non-Hodgkin lymphoma: a first-in-human, multicentre, open-label, single-arm, phase 1 study.
Dai Maruyama, Eric Jacobsen, Pierluigi Porcu, Pamela Allen, Kenji Ishitsuka
The Lancet. Oncology. 2024-12-01
Treatment Patterns and Outcomes in Follicular Lymphoma with POD24: An Analysis from The LEO Consortium.
Jonathan R Day, Melissa C Larson, Urshila Durani, Jean L Koff, Yucai Wang
Blood Advances. 2024-11-27
Hematological Oncology journal women in lymphoma special issue: Latest updates in nodal peripheral T-cell lymphoma.
Limei Poon, Laurence de Leval, Siok Bian Ng, Yuqin Song, Barbara Pro
Hematological Oncology. 2024-11-01

Journal Articles

Five-Year Follow-up of Lenalidomide plus Rituximab as Initial Treatment for Mantle Cell Lymphoma
Jia Ruan, Jakub Svoboda, John P Leonard, Sonali M Smith, Morton Coleman, Richard R Furman, Blood

Abstracts/Posters

A Phase II, Multicenter Study of High Dose Chemotherapy with Autologous Stem Cell Transplant Followed By Maintenance Therapy with Romidepsin for T-Cell Lymphoma
Jia Ruan, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019
Phase 2 Results of the iR2 Regimen (Ibrutinib, Lenalidomide, and Rituximab) in Patients with Relapsed/Refractory (R/R) Non-Germinal Center B Cell_like (Non-GCB) Diffus...
Jia Ruan, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019
Pembrolizumab and Copanlisib for the Treatment of Relapsed or Refractory Mature T-Cell Lymphomas
Jia Ruan, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019
Final Results of a Phase II Biomarker-Driven Study of Ruxolitinib in Relapsed and Refractory T-Cell Lymphoma
Jia Ruan, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019
Evaluation of the Functional Landscape of Systemic Immunity in Classical Hodgkin Using a Novel Single Cell Platform (Isolight)
Jia Ruan, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019
Composite Copy Number Variation in CDK4, CDKN2A and RB1 Predisposes Mantle Cell Lymphoma to Expansion of PD1+ Tumor Cells and Resistance to CDK4/6 Inhibitor Therapy as...
Jia Ruan, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/7/2019
Join now to see all

Lectures

Aggressive Non-Hodgkin Lymphomas: It's Getting Personal
61st Annual American Society of Hematology Meeting - Orlando, FL - 12/7/2019
Hematopoietic Stem Cell Transplant in Novel Agent Era Is Associated with Improved Survival in Relapsed and Refractory Peripheral T-Cell Lymphoma
2018 ASH Annual Meeting - San Diego, CA - 12/1/2018

Press Mentions

Adding Azacitidine to Standard Chemotherapy May Be Effective for Patients with PTCL-TFHMay 15th, 2023
Epigenetic Drug Aids Chemotherapy in Lymphoma StudyMay 9th, 2023
Ibrutinib Helps Treat CNS Relapse in Mantle Cell LymphomaNovember 16th, 2022
Join now to see all

Professional Memberships

American Society of Clinical Oncology - ASCO
Member
American Society of Hematology - ASH
Member

Other Languages

Chinese (Mandarin)

Insurance Accepted

Aetna Choice POS II
Aetna HMO
BCBS Blue Card PPO
BCBS Florida NetworkBlue
BCBS Florida Preferred Patient Care PPO
CIGNA HMO
CIGNA Open Access
CIGNA PPO
Empire BCBS HMO
Empire BCBS PPO
First Choice
GHI PPO
Great West PPO
HIP of New York - Select PPO
Humana ChoiceCare Network PPO
Lifewise Health Plan of Oregon
Multiplan PHCS PPO
Multiplan PPO
MVP Healthcare PPO
ODS Network
Oxford Health Freedom
Oxford Health Liberty
PacificSource Preferred PSN
Providence Health System Personal Option
Providence Health System Preferred PPO
Regence Oregon - Preferred Provider Network
United Healthcare - Direct Choice Plus POS
United Healthcare - Direct Options PPO
Please verify your coverage with the provider's office directly when scheduling an appointment